第九章 药品综合评价在国内外医保药品和基本药物相关管理中的应用  

Chapter 9 Application of Comprehensive Drug Evaluation in the Management of Medical Insurance Drugs and Essential Drugs at Home and Abroad

作　　者：赵冠宏[1] 沈素[2] ZHAO Guanhong;SHEN Su(Medical Insurance Office,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China;Department of Pharmacy,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)

机构地区：[1]首都医科大学附属北京友谊医院医疗保险办公室,北京100050 [2]首都医科大学附属北京友谊医院药剂科,北京100050

出　　处：《临床药物治疗杂志》2024年第S1期52-59,73,共9页Clinical Medication Journal

摘　　要：我国在国家基本医疗保险、国家基本药物管理政策和制度的完善过程中,药品综合评价在药品目录遴选与调整中发挥着关键作用。利用药品综合评价体系通过对药品进行多维度、多层次的评价,包括有效性、安全性、经济性、创新性和公平性等方面确定遴选药品目录,经过多年探索与实践,逐渐发展完善。通过卫生技术评估方法,综合评价创新药物,为相关准入决策和临床合理用药提供循证支持。本章通过回顾我国医疗卫生体制机制改革中医疗保险和基本药物的实施现状,简要总结归纳了国际上部分国家和地区的基本药物管理特点,以期对我国在政策制定与具体实施层面有所帮助。建立并逐步完善基于政策协同、信息共享,满足多主体参与、多维度分析需求的中国药品临床综合评价机制,以循证方式开展综合评价,已成为药品目录调整的重要工具。In the process of perfecting the national basic medical insurance and national basic drug management policies and systems,comprehensive drug evaluation plays a key role in the selection and adjustment of the drug catalog.By using the comprehensive drug evaluation system to evaluate drugs from multiple dimensions and levels,including effectiveness,safety,economy,innovation,and fairness,the drug catalog is determined.After years of exploration and practice,the comprehensive drug evaluation system has been gradually developed and improved.By using health technology assessment methods,innovative drugs are comprehensively evaluated to provides evidence-based support for relevant entry decisionmaking and clinical rational drug use.This article reviews the current status of medical insurance and essential drug use in China's healthcare system reform and briefly summarizes the characteristics of essential drug management in some countries and regions around the world to provide some help for policy formulation and specific implementation in China.Building and gradually improving a clinical comprehensive drug evaluation mechanism which is based on policy coordination and information sharing and meets the needs of multiple stakeholders participation and multi-dimensional analysis,and conducting comprehensive drug evaluation with an evidence-based approach have become important tools for drug list adjustment in China.

关 键 词：药品综合评价 卫生技术评估 国家基本医疗保险 国家基本药物 

分 类 号：R95[医药卫生—药学]